

Resource Summary Report

Generated by ASWG on Aug 15, 2026

Recombinant Anti-CD39 antibody [EPR20627]

RRID:AB_2889212

Type: Antibody

Proper Citation

Abcam Cat# ab223842, RRID:AB_2889212

Antibody Information

URL: http://antibodyregistry.org/AB_2889212

Proper Citation: Abcam Cat# ab223842, RRID:AB_2889212

Target Antigen: CD39

Clonality: recombinant monoclonal

Antibody Name: Recombinant Anti-CD39 antibody [EPR20627]

Description: This recombinant monoclonal targets CD39

Clone ID: EPR20627

Antibody ID: AB_2889212

Vendor: Abcam

Catalog Number: ab223842

Record Creation Time: 20250819T215546+0000

Record Last Update: 20250820T003314+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CD39 antibody [EPR20627].

No alerts have been found for Recombinant Anti-CD39 antibody [EPR20627].

Data and Source Information

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Sardarni UK, et al. (2026) Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. Cancer research communications, 6(5), 1036.

Li H, et al. (2025) Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer cell, 43(4), 757.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. Cell reports. Medicine, 102360.

Tian M, et al. (2025) Deconstructing the intercellular interactome in vascular dementia with focal ischemia for therapeutic applications. Cell.

Ning J, et al. (2024) Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. Cell reports. Medicine, 5(5), 101505.

Anderson AE, et al. (2024) Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors. Molecular cancer therapeutics, 23(10), 1471.

Reynolds KE, et al. (2024) Dysregulated Purinergic Signalling in Fragile X Syndrome Cortical Astrocytes. Neuromolecular medicine, 26(1), 36.

Li J, et al. (2024) Amitriptyline revitalizes ICB response via dually inhibiting Kyn/Indole and 5-HT pathways of tryptophan metabolism in ovarian cancer. iScience, 27(12), 111488.

Duan J, et al. (2023) Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. Cell reports. Medicine, 4(12), 101302.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer cell, 41(5), 837.

Schwabenland M, et al. (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity, 54(7), 1594.